These success, together with a prior report showing that a little-molecule ACKR3 agonist CCX771 exhibits anxiolytic-like habits in mice,2 guidance the strategy of targeting ACKR3 as a unique strategy to modulate the opioid process, which could open up new therapeutic avenues for opioid-associated disorders. A investigation review released in https://juniuse061sjy6.blogolenta.com/profile